<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108534</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-01535BD1-01</org_study_id>
    <secondary_id>2016-003672-47</secondary_id>
    <nct_id>NCT03108534</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.</brief_title>
  <official_title>A Single Dose, Randomised, Double Blind, Double Dummy, Placebo Controlled, 3-way Crossover Clinical Study, Comparing the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 100/6 µg NEXThaler® Versus CHF1535 100/6 µg pMDI in Asthmatic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is designed to evaluate the non-inferiority of CHF1535 100/6 µg NEXThaler
      versus CHF1535 100/6 µg pMDI on the onset of relief from methacholine-induced bronchospasm,
      in terms of pulmonary function (i.e. change in Forced Expiratory Volume in the 1st second,
      FEV1, from baseline to 5 min after study drug intake) in asthmatic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Actual">September 19, 2017</completion_date>
  <primary_completion_date type="Actual">September 19, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 5-min post-dose</measure>
    <time_frame>5 min post-dose</time_frame>
    <description>Change in FEV1 from baseline (baseline is the post-diluent value, before methacholine challenge test)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 other time points</measure>
    <time_frame>Up to 30 min post-dose</time_frame>
    <description>Change in FEV1 from baseline (baseline is the post-diluent value, before methacholine challenge test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-10min</measure>
    <time_frame>From dosing to 10 min post-dose</time_frame>
    <description>FEV1 area under the curve from dosing to 10 min post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery in FEV1</measure>
    <time_frame>From dosing to 30 min post-dose</time_frame>
    <description>Time to return to 85% of baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Borg scale</measure>
    <time_frame>Up to 30 min post-dose</time_frame>
    <description>Change in Borg scale from the end of the methacholine challenge test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery in Borg scale</measure>
    <time_frame>Up to 30 min post-dose</time_frame>
    <description>50% decrease from the post-methacholine challenge value</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF1535 NEXThaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF1535 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 NEXThaler</intervention_name>
    <description>Rescue treatment</description>
    <arm_group_label>CHF1535 NEXThaler</arm_group_label>
    <other_name>Foster NEXThaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 pMDI</intervention_name>
    <description>Rescue treatment</description>
    <arm_group_label>CHF1535 pMDI</arm_group_label>
    <other_name>Foster</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Rescue treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form obtained

          -  Minimum required Peak Inspiratory Flow (PIF) to activate NEXThaler

          -  Pre-bronchodilator FEV1 of at least 65%

          -  Positive response to methacholine challenge test

          -  Previous treatment with low-medium doses of Inhaled Corticosteroids (ICS) or
             ICS/Long-acting beta2-agonist (LABA) as per Global Initiative for Asthma (GINA) 2016
             guidelines

          -  For females: non-pregnant, non-lactacting and using highly effective contraceptive
             methods.

        Exclusion Criteria:

          -  Clinically relevant and uncontrolled concomitant diseases

          -  Abnormal clinically relevant ECG

          -  Presence of aortic aneurism

          -  Uncontrolled hypertension

          -  Intake of non-permitted concomitant medications

          -  Participation in another clinical trials in the previous 8 weeks

          -  Seasonal variation in asthma

          -  Recent occurrence of asthma exacerbations

          -  Hypersensitivity to any product used in the trial, including excipients

          -  Heavy caffeine drinkers

          -  History of alcohol/drug abuse

          -  Smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Dundee</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

